1. Home
  2. ADPT vs CMRE Comparison

ADPT vs CMRE Comparison

Compare ADPT & CMRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADPT
  • CMRE
  • Stock Information
  • Founded
  • ADPT 2009
  • CMRE 1974
  • Country
  • ADPT United States
  • CMRE Monaco
  • Employees
  • ADPT N/A
  • CMRE N/A
  • Industry
  • ADPT Biotechnology: Biological Products (No Diagnostic Substances)
  • CMRE Marine Transportation
  • Sector
  • ADPT Health Care
  • CMRE Consumer Discretionary
  • Exchange
  • ADPT Nasdaq
  • CMRE Nasdaq
  • Market Cap
  • ADPT 1.1B
  • CMRE 1.0B
  • IPO Year
  • ADPT 2019
  • CMRE 2010
  • Fundamental
  • Price
  • ADPT $9.03
  • CMRE $7.77
  • Analyst Decision
  • ADPT Buy
  • CMRE Hold
  • Analyst Count
  • ADPT 6
  • CMRE 2
  • Target Price
  • ADPT $9.83
  • CMRE $13.50
  • AVG Volume (30 Days)
  • ADPT 3.0M
  • CMRE 521.9K
  • Earning Date
  • ADPT 05-01-2025
  • CMRE 05-08-2025
  • Dividend Yield
  • ADPT N/A
  • CMRE 5.99%
  • EPS Growth
  • ADPT N/A
  • CMRE N/A
  • EPS
  • ADPT N/A
  • CMRE 2.44
  • Revenue
  • ADPT $189,527,000.00
  • CMRE $2,054,690,000.00
  • Revenue This Year
  • ADPT $21.20
  • CMRE N/A
  • Revenue Next Year
  • ADPT $21.99
  • CMRE N/A
  • P/E Ratio
  • ADPT N/A
  • CMRE $3.19
  • Revenue Growth
  • ADPT 8.61
  • CMRE 18.22
  • 52 Week Low
  • ADPT $2.99
  • CMRE $6.63
  • 52 Week High
  • ADPT $10.28
  • CMRE $17.58
  • Technical
  • Relative Strength Index (RSI)
  • ADPT 57.82
  • CMRE 36.00
  • Support Level
  • ADPT $8.38
  • CMRE $6.63
  • Resistance Level
  • ADPT $9.51
  • CMRE $9.68
  • Average True Range (ATR)
  • ADPT 0.66
  • CMRE 0.29
  • MACD
  • ADPT 0.16
  • CMRE -0.12
  • Stochastic Oscillator
  • ADPT 63.02
  • CMRE 37.38

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

About CMRE Costamare Inc. $0.0001 par value

Costamare Inc is an international owner and operator of containerships and dry bulk vessels. The company charter its containerships to the liner companies, providing transportation of containerized cargoes. It charter its dry bulk vessels to a wide variety of customers, providing transportation for dry bulk cargoes. The company's fleet of vessels includes Cosco Guangzhou, Cosco Ningbo, Cosco Yantian, Vantage, Valor, Valiant, Maersk Kobe, and among others. Costamare provides services to ocean carriers that demand a high standard of safety and reliability. It generates a majority of its revenue from the United States of America.

Share on Social Networks: